{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:46:33Z","timestamp":1792813593390,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejca.2021.07.035","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T06:38:30Z","timestamp":1630046310000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy\u00a0or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-7538","authenticated-orcid":false,"given":"Martin","family":"Faehling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Fallscheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kramberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Str\u00e4ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"S\u00e4tzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Heinzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.07.035_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.ejca.2021.07.035_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1164\/rccm.201702-0433CI","article-title":"AJRCCM: 100-year anniversary. The shifting landscape for lung cancer: past, present, and future","volume":"195","author":"Vachani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejca.2021.07.035_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"PACIFIC investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.035_bib4","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib6","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.035_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2021.07.035_bib8","first-page":"S1470","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib9","first-page":"CT003","article-title":"Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","author":"Forde","year":"2021","journal-title":"AACR"},{"key":"10.1016\/j.ejca.2021.07.035_bib10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for radiotherapy and oncology and European Organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.035_bib12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189 investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.035_bib13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"KEYNOTE-407 investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.035_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2019.05.027","article-title":"Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer","volume":"134","author":"Melosky","year":"2019","journal-title":"Lung Canc"},{"key":"10.1016\/j.ejca.2021.07.035_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.07.035_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2021.07.035_bib18","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2021.07.035_bib19","doi-asserted-by":"crossref","first-page":"i5239","DOI":"10.1136\/bmj.i5239","article-title":"PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2021.07.035_bib20","series-title":"TNM classification of malignant tumors","isbn-type":"print","year":"2016","ISBN":"https:\/\/id.crossref.org\/isbn\/9781119263579"},{"key":"10.1016\/j.ejca.2021.07.035_bib21","article-title":"Feasibility of neo-adjuvant (chemo)immunotherapy as part of definitive multimodal treatment of Non-small cell lung cancer (NSCLC): a prospective real-world-analysis (A1924\/1006)","author":"Faehling","year":"2019"},{"key":"10.1016\/j.ejca.2021.07.035_bib22","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small- cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib25","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.jtho.2019.08.1595","article-title":"Nodal immune flare (NIF) following neoadjuvant anti-PD-1 and anti-CTLA-4 therapy in non-small cell lung cancer","volume":"14","author":"Sepesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2021.07.035_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Canc"},{"key":"10.1016\/j.ejca.2021.07.035_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2019.03.012","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","author":"Kerr","year":"2019","journal-title":"Lung Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:38Z","timestamp":1760733218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"alternative-id":["S0959804921004937"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy\u00a0or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}